Brazil Halts Dengue Vaccine After Two Deaths

Brazil has temporarily suspended the use of the world's first single-dose dengue vaccine. This decision was made on June 8, 2026, following two suspicious deaths among those who received the inoculation.

More than 501,044 people received doses of the vaccine between January and May. While most vaccinations proceeded without issue, 3,703 individuals, or 0.7 percent, experienced symptoms similar to dengue. Forty-two individuals reported more severe reactions.

Authorities are investigating three severe cases, two of which were fatal. The two deceased were a 58-year-old man and a 48-year-old woman. A 38-year-old woman, who had been in intensive care, has since been discharged.

Health Minister Alexandre Padilha stated there is insufficient data to confirm a causal link between the vaccine and these severe outcomes. However, he emphasized the warning signals necessitated a precautionary suspension of vaccination efforts.

The adverse effects were unexpected, as trials involving over 16,000 volunteers across 14 Brazilian states did not reveal such issues. These trials had previously indicated an efficacy rate of 91.6 percent against severe dengue.

This single-dose vaccine, developed publicly in Brazil and approved in November, aimed to simplify mass vaccination campaigns. The only other available dengue vaccine requires two doses taken three months apart.